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 ABSTRACT  
Despite its potent in vitro anti-cancer activity, the vitamin E extract tocotrienol has its 
therapeutic potential hampered by its poor bioavailability and by its inability to reach tumors 
in a specific way after intravenous administration. One possibility to overcome this issue 
would be to entrap tocotrienol within vesicles bearing transferrin, whose receptors are present 
in abundance on many cancer cell types. In this study, we demonstrated that the systemic 
administration of tocotrienol entrapped within transferrin-bearing vesicles led to tumor 
suppression of 20% of A431 epidermoid carcinoma tumors and 50% of B16-F10 melanoma 
tumors at the end of the treatment. The survival of animals treated with these vesicles was 
improved by more than 20 days in comparison with the controls, for the two cancer models 
tested. Animals did not show any secondary effects following administration of the treatment. 
The entrapment of tocotrienol within transferrin-bearing vesicles is therefore a promising 
therapeutic strategy, which could result in tumor suppression after systemic administration of 
this delivery system.   
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GRAPHICAL ABSTRACT 
Bioluminescence imaging of the tumor regression resulting from the intravenous 
administration of transferrin-bearing vesicles entrapping tocotrienol, in a mouse bearing 
subcutaneous B16-F10-luc tumors. (Controls: untreated tumors).   
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INTRODUCTION 
Tocotrienol, a compound of the vitamin E family, has recently gained considerable attention 
due to its potent anti-cancer activity displayed in vitro on many types of cancer, including 
prostate, breast, pancreatic, colorectal, lung and liver cancer [1- 4]. It has also been used as a 
therapeutic adjuvant, leading to synergistic anti-proliferative effects when associated with 
various anti-cancer drugs such as tamoxifen, celecoxib and gemcitabine [5-9]. However, its 
therapeutic use against cancer in vivo has been prevented by its poor bioavailability and its 
inability to specifically reach tumors. In order to overcome these problems, we recently 
entrapped the tocotrienol-rich fraction (TRF) of palm oil in tumor-targeted vesicles bearing 
transferrin [10]. Transferrin (Tf) is a particularly interesting ligand for active tumor targeting, 
as its receptors are expressed in abundance on many types of cancers [11]. Transferrin-
bearing vesicles provides a tumor-selective targeting strategy in addition to its passive 
targeting, resulting from the enhanced permeability and retention of particulate delivery 
systems in tumors [12]. Transferrin has been widely used as a tumor-targeting agent for 
tumor-targeted drug and gene delivery [11, 13-17]. We recently demonstrated that the 
intravenous injection of transferrin-conjugated vesicles entrapping TRF resulted in regression 
of the tumors shortly after administration of the treatment. However, this therapeutic effect 
was short-lived and only lasted for the duration of the treatment. We now seek to increase this 
therapeutic effect by optimizing the frequency of administration of the TRF vesicle 
formulation. The objectives of this work are therefore to assess the in vivo therapeutic efficacy 
of this optimized treatment. 
 
 
 
 5 
MATERIALS AND METHODS 
Materials 
Tocotrienol Rich Fraction (TRF) of palm oil corresponds to a mixture of various tocotrienol 
isomHUV  Į-WRFRWULHQRO  į-WRFRWULHQRO DQG  Ȗ-WRFRWULHQRO  Į-
tocopherol, and other tocotrienol-related compounds. TRF was a kind gift from Dr. Abdul 
Gapor (Malaysian Palm Oil Board, Kuala Lumpur, Malaysia).  
Solulan C24 came from Amerchol (Edison, NJ). A431 human epidermoid carcinoma and 
Bioware® B16-F10-luc-G5 mouse melanoma expressing the firefly luciferase, were 
respectively obtained from the European Collection of Cell Cultures and from Caliper Life 
Sciences (Hopkinton, MA). Media needed for the culture of these cells was purchased from 
Invitrogen (Paisley, UK). All other reagents and chemicals that are not specifically mentioned 
below were purchased from Sigma Aldrich (Poole, UK).  
 
Preparation of transferrin-bearing vesicles entrapping TRF  
Transferrin-conjugated vesicles entrapping TRF were prepared and characterized as 
previously described [10]. To prepare control vesicles entrapping TRF, a mixture of sorbitan 
monostearate (Span 60; 65 mg), cholesterol (58 mg), Solulan C24 (54 mg) in 2 mL TRF 
solution (0.5 mg/mL, prepared in dimethylsulfoxide) was shaken at 60oC for 1 hour, before 
being probe sonicated with a Soniprep 150 (MSE, United Kingdom) for 4 min. Tf-bearing 
vesicles were then prepared by conjugating Tf (6 mg) to the control vesicles (2 mL), using 
dimethylsuberimidate as a cross-linker [10].  
Unentrapped TRF, dimethylsulfoxide, free Tf and dimethylsuberimidate were removed by 
ultracentrifugation (150 000 g for 1h). The drug loaded vesicle pellet was then resuspended in 
2 ml PBS.   
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TRF loading in the vesicles was measured by spectrofluorimetry Ȝex QP Ȝem 325nm) 
using a Varian Cary eclipse fluorescence spectrophotometer (Agilent Technologies, CA) after  
disruption of the vesicles with isopropanol. 
 
Cell culture 
A431 and B16-F10-luc-G5 cancer cell lines overexpressing transferrin receptors were 
respectively cultivated in DMEM or RPMI-1640 medium supplemented with 10% (v/v) fetal 
bovine serum, 1% (v/v) L-glutamine and 0.5% (v/v) penicillin-streptomycin, in a humidified 
atmosphere of 5% CO2 at 37oC. 
 
In vivo tumoricidal activity  
The in vivo experiments in this study were approved by the local ethics committee and were 
conducted according to the UK Home Office regulations. 
A431 and B16-F10-luc-G5 cells were subcutaneously injected to both flanks of female 
immunodeficient BALB/c mice (1 x 10 6 cells per flank). Vascularized tumors, with a typical 
diameter of 5 mm, were palpable 6 days after implantation of the cells. The mice were then 
intravenously injected via the tail vein with TRF entrapped in Tf-bearing vesicles, control 
vesicles or in solution (10 µg TRF per injection for all treatments, 5 mice per treatment). The 
administration of the treatment was done once daily for 20 days.  
The weight of the animals was measured daily as a surrogate marker of toxicity. The volume 
of the tumors was also determined daily, by caliper measurements (volume = d3 [ʌ At the 
end of the experiment, the tumor response to treatment was classified according to the 
Response Evaluation Criteria in Solid Tumors [18]: progressive disease, when the relative 
tumor volume has increased by at least 1.2-fold compared to its volume at the start of the 
experiment, stable disease when the relative tumor volume is comprised between 0.7 and 1.2-
 7 
fold compared to its starting volume, partial response when the relative tumor volume is 
smaller or equal to 0.7-fold, and complete response when the tumor has completely 
disappeared.  
The therapeutic efficacy of the treatments was also assessed by bioluminescence imaging, 
using an IVIS Spectrum (Caliper Life Sciences, MA). Mice bearing subcutaneous B16-F10-
luc-G5 tumors were intravenously injected with the treatments described above. Ten minutes 
before imaging, they were intraperitoneally injected with D-luciferin, the substrate of 
luciferase (150 mg D-luciferin /kg body weight) and anaesthetized by isoflurane inhalation on 
Days 1, 3, 5, 7, 9 and 11 of the experiment. D-luciferin±expressing bioluminescent tumors 
were able to emit some light, which was detected for a constant duration of 2 min using 
Living Image® software. All images were acquired using the same illumination settings. 
 
Statistical Analysis 
Results were expressed as means ± standard error of the mean (S.E.M). Statistical 
significance was assessed by one-way analysis of variance (ANOVA) and Tukey multiple 
comparison post-test (Minitab® software, State College, PE). Differences were considered 
statistically significant for P values lower than 0.05. 
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RESULTS  
Intravenously administered TRF entrapped in Tf-bearing vesicles led to tumor regression 
within 72 hours on A431 tumors (Fig. 1A). This effect was maintained for 15 days, allowing 
the majority of the tumors to reach a size about half their initial size. From Day 15, while 
some tumors kept regressing, others started growing, which led to an overall slowdown of 
A431 tumor growth in comparison to the tumor growth observed following administration of 
the other treatments. From Day 24, the mice bearing growing tumors reaching the maximum 
allowed size (13 mm) had to be euthanized. The other mice, with tumors smaller than 13 mm 
diameter, were kept in the study. By contrast, none of the other treatments resulted in any 
A431 tumor regression. The effects on tumor growth observed following treatment with Tf-
bearing vesicles entrapping TRF were significantly different from those resulting from the 
other treatments.  
The replacement of A431 tumors by B16-F10-Luc tumors resulted in a different pattern of 
tumor growth. The treatment with TRF entrapped in Tf-bearing vesicles led to the decrease of 
all tumors for the 3 first days of the experiment (Fig. 1B). From Day 3, although some tumors 
kept regressing, others started growing, which led to an overall B16-F10 tumor growth similar 
to that observed following treatment with control vesicles until Day 7. From Day 7, the mice 
bearing tumors that reached the maximum allowed size had to be euthanized. The overall 
tumor size was decreasing from Day 7 to Day 25, until two of the tumors which were 
regressing started growing again, resulting in the sacrifice of the mouse carrying them at Day 
28.  The experiment was prolonged by 3 days compared to the A431 tumor growth 
experiment to assess if any other tumors would start growing again, which was not the case. 
For this cell line as well, none of the other treatments resulted in tumor regression. The effects 
on tumor growth observed following treatment with Tf-bearing vesicles entrapping TRF were 
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significantly different from those resulting from the other treatments from Day 8 to Day 33 
(end of the experiment). 
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Fig. (1). Tumor growth studies following systemic administration of Tf-bearing vesicles 
entrapping TRF (10 µg/injection) (green) in a mouse bearing A431 tumors (A) or B16-F10-
Luc tumors (B). Controls:  control vesicles (without Tf) entrapping TRF (orange), TRF 
solution (red), untreated tumors (black) (inset: magnification of Figure 1A) (n=10). 
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Bioluminescence imaging qualitatively confirmed the tumoricidal activity of TRF entrapped 
in Tf-vesicles (Fig. 2). B16-F10-luc tumors treated with Tf-vesicles entrapping TRF regressed 
at Day 5, before completely disappearing from Day 7. On the other hand, all the other 
treatments resulted in tumor growth. 
 12 
 
 
Fig. (2).   Bioluminescence imaging of the tumoricidal activity of TRF entrapped in Tf-
bearing vesicles in mice bearing subcutaneous B16-F10-luc tumors. Controls: TRF 
administered as entrapped in control vesicles or in solution, untreated tumors. The scale 
indicates surface radiance (photons/s/cm2/steradian).  
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The administration of TRF entrapped in vesicles or in solution was well tolerated by the mice 
and no visible signs of toxicity or significant weight loss were observed during the study (Fig. 
3). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3).   Variations of the animal body weight following systemic administration of Tf-
bearing vesicles entrapping TRF (10 µg/injection) (green) in a mouse bearing A431 tumors 
(A) or B16-F10-Luc tumors (B). Controls:  TRF administered as entrapped in control vesicles 
(orange) or in solution (red), untreated tumors (black) (n=10). 
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On the last day of the experiment, treatment with Tf-bearing vesicles entrapping TRF resulted 
in complete tumor disappearance for 20% of A431 tumors and tumor regression for another 
20% of A431 tumors (Fig. 4A). Treatment with control vesicles also led to tumor regression, 
but with the less positive outcome of 10% partial response and 10% stable response. On the 
other hand, all the tumors treated with TRF solution or left untreated were growing.  
The tumor response to treatment was more successful for B16-F10 tumors. On the last day of 
the experiment, 50% of B16-F10 tumors treated with Tf-bearing vesicles entrapping TRF had 
completely disappeared, while another 10% of tumors had regressed (Fig. 4B). By contrast, 
all the other treatments resulted in 100% tumor growth.  
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Fig. (4). Overall tumor response to treatments following systemic administration of Tf-
bearing vesicles entrapping TRF (10 µg/injection) in a mouse bearing A431 tumors (A) or 
B16-F10-Luc tumors (B). Controls: TRF entrapped in control vesicles or in solution, 
untreated tumors (n=10). 
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As a result of this improved therapeutic effect, the survival of A431 tumors-bearing mice 
treated with Tf-bearing and control vesicles was extended by 23 days and 8 days respectively, 
in comparison with the mice receiving no treatment (Fig. 5A). The survival was even 
improved on B16-F10 tumors-bearing mice, as it was respectively extended by 26 days and 3 
days after treatment with Tf-bearing and control vesicles, compared to untreated mice (Fig. 
5B). However, the administration of TRF solution did not extend the survival of the animals 
compared to untreated mice with both tumor cell lines. 
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Fig. (5). Cumulative survival rate of mice bearing A431 tumors (A) or B16-F10-Luc tumors 
(B) following systemic administration of Tf-bearing vesicles entrapping TRF (10 
µg/injection) (green). Controls: TRF entrapped in control vesicles (orange) or in solution 
(red), untreated tumors (black) (n=10).  
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DISCUSSION  
Although highly promising in vitro, the use of the tocotrienol for the treatment of cancer has 
mainly been hampered by the inability of this drug to specifically reach tumors following 
systemic injection. To overcome this issue, we hypothesized that entrapping TRF in drug 
delivery systems bearing transferrin, whose receptors are present in abundance on cancer 
cells, would increase the amount of drug delivered to cancer cells and therefore increase its 
therapeutic efficacy. 
In this study, the intravenous injection of tocotrienol entrapped in transferrin-bearing vesicles 
led to a complete tumor disappearance of 20% of A431 tumors and 50% of B16-F10 tumors. 
Consequently, tumor-bearing mice treated with this formulation showed an extended survival 
of more than 20 days compared to untreated mice.  
This work corresponds to a major improvement of the therapeutic efficacy of this drug for the 
treatment of tumors. Tocotrienol co-encapsulated with simvastatin in lipid nanoparticles had 
already been shown to have an improved anti-proliferative effect against +SA mammary 
epithelial cancer cell line, in comparison with control Į-tocopherol nanoparticles (with 
respective IC50 of 0.52 µM and 17.7 µM) in in vitro experiments. However, no in vivo results 
have been reported with this delivery system so far [19]. In our previous studies with the 
Solulan-based vesicles, we demonstrated that the systemic administration of TRF entrapped in 
Tf-bearing vesicles were able to decrease the size of A431 tumors, but only for the duration of 
the treatment, which was 10 days [10]. All the tumors then grew back after halting the 
treatment. None of them disappeared at any time when treated with only 10 injections.  By 
contrast, our current regimen of administration of 20 injections increased the therapeutic 
effect on both tested tumors, resulting in complete disappearance of 20% and 50% of them, 
respectively. In addition, this therapeutic effect was maintained after halting the treatment. 
The results obtained in this current study were even improved compared with those obtained 
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with our intravenously administered Tf-conjugated, tocopheryl-based multilamellar vesicles 
entrapping tocotrienol, which resulted in tumor eradication of 20% of A431 tumors and 40% 
of B16-F10 tumors [16]. These results demonstrate that tocotrienol is able to exert an anti-
cancer therapeutic effect in vivo, not only as a tumor growth inhibitor or as a therapeutic 
adjuvant as previously described [1, 20], provided it is targeted to the tumors. In addition, this 
targeted nanomedicine was able to reach subcutaneous tumor models overexpressing 
transferrin receptors, following intravenous injection and should therefore have the potential 
to reach metastatic tumors disseminated in the body.  
The mechanism of action used by tocotrienol to exert its therapeutic effect in our study is still 
unknown. Tocotrienol has been shown to be able to activate p53, induce apoptosis and 
modulate Bax/Bcl-2 ratio [21].  In addition, it can inhibit angiogenesis by down regulating the 
expression of the vascular endothelial growth factor receptor [22]. It also exerts its anti-cancer 
effect by inhibiting DNA polymerase and telomerase, enzymes involved in the proliferation 
of cancer cells [23-24]. The extent of the therapeutic effect observed in our study made us 
suggest that many of these mechanisms were involved in the anti-cancer effect observed. 
There may be scope for further improvements in the in vivo activity of these nanomedicines 
by understanding the mechanisms behind the variability of the response between individual 
tumors, hopefully resulting in a further optimized therapeutic effect against tumors. 
These therapeutic effects and the good tolerability of the treatments potentially make the 
transferrin-conjugated vesicles entrapping tocotrienol a highly promising nanomedicine, 
which will be further investigated.  
 
 20 
CONCLUSION 
The entrapment of tocotrienol in transferrin-conjugated vesicles significantly increased the 
therapeutic efficacy of tocotrienol in vivo compared to the drug solution. The systemic 
injection of tocotrienol entrapped in these targeted vesicles resulted in the disappearance of 
20% of A431 tumors and 50% of B16-F10 tumors on the last day of the experiment. 
Consequently, the survival of the tumor-bearing mice was extended by more than 20 days 
compared to untreated mice, on both cancer cell lines. Transferrin-vesicles entrapping 
tocotrienol is therefore a highly promising therapeutic system which deserves further 
investigation.   
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FIGURE LEGENDS 
Fig. (1). Tumor growth studies following systemic administration of Tf-bearing vesicles 
entrapping TRF (10 µg/injection) (green) in a mouse bearing A431 tumors (A) or B16-F10-
Luc tumors (B). Controls:  control vesicles (without Tf) entrapping TRF (orange), TRF 
solution (red), untreated tumors (black) (inset: magnification of Figure 1A) (n=10). 
 
Fig. (2).   Bioluminescence imaging of the tumoricidal activity of TRF entrapped in Tf-
bearing vesicles in mice bearing subcutaneous B16-F10-luc tumors. Controls: TRF 
administered as entrapped in control vesicles or in solution, untreated tumors. The scale 
indicates surface radiance (photons/s/cm2/steradian).  
 
Fig. (3).   Variations of the animal body weight following systemic administration of Tf-
bearing vesicles entrapping TRF (10 µg/injection) (green) in a mouse bearing A431 tumors 
(A) or B16-F10-Luc tumors (B). Controls:  TRF administered as entrapped in control vesicles 
(orange) or in solution (red), untreated tumors (black) (n=10). 
 
Fig. (4). Overall tumor response to treatments following systemic administration of Tf-
bearing vesicles entrapping TRF (10 µg/injection) in a mouse bearing A431 tumors (A) or 
B16-F10-Luc tumors (B). Controls: TRF entrapped in control vesicles or in solution, 
untreated tumors (n=10). 
 
Fig. (5). Cumulative survival rate of mice bearing A431 tumors (A) or B16-F10-Luc tumors 
(B) following systemic administration of Tf-bearing vesicles entrapping TRF (10 
µg/injection) (green). Controls: TRF entrapped in control vesicles (orange) or in solution 
(red), untreated tumors (black) (n=10).   
